Gilead completes acquisition of Tubulis for $3.15 billion upfront

• Gilead completed its acquisition of Germany-based Tubulis, adding a clinical-stage antibody-drug conjugate platform to its oncology portfolio.
• The deal terms include USD 3.15 billion paid upfront on a cash-free, debt-free basis, with up to USD 1.85 billion tied to contingent milestone payments.
• The transaction adds Tubulis’ lead program TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC being studied in platinum-resistant ovarian cancer.
• Tubulis’ team will remain in Munich, forming the Tubulis ADC Innovation Center to support discovery, manufacturing, and clinical development of next-generation ADCs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605210930BIZWIRE_USPR_____20260520_BW959712) on May 21, 2026, and is solely responsible for the information contained therein.